If you like increased domestic spying – and the increase in government spending and crony opportunities that follow and allowing law enforcement to seize people’s property without a conviction, then William Barr may be your man for Attorney General.

Should we feel sorry for the DEA agent caught accepting bribes in exchange for providing information to drug dealers – no. Should we FINALLY realize the drug war is a complete failure and should end now – yes.

With a projected market of $57 billion by 2027, it won’t be long before the legalized marijuana market is controlled by the mega-corporations.

Whistleblower evidence from 2017 may help shine a light on the alleged illegal activities conducted by the Clinton Foundation.

Rahm Emanuel became Mayor of Chicago promising to cut wasteful and excessive spending and instead handed out over $481 million in extra pay for Chicago city employees in 2017.

Excessive government regulations and taxes on small businesses along with subsidies and incentives to large corporations is slowly and steadily reducing (or eliminating) the most essential factor of a successful capitalistic system – competition.

Drug company execs who used bribes, parties, and lavish dinners to get doctors to overprescribe one of the world’s most powerful and dangerous opioid drugs are facing criminal charges while the company struggles to survive.

When Congress abdicates that duty to the regulation writers, it makes cronyism even worse.

It’s no surprise that in an era of massive government spending and rampant cronyism that the top five counties in the U.S. with the wealthiest households are all suburbs of Washington, D.C.

In a country of murky regulations and even murkier politics, U.S. companies doing business with China should be even more cautious than normal after Canada’s arrest of Huawei’s CFO.

First it was electronic surveillance, now it’s sanction violations. China’s Huawei, one of the biggest competitors of U.S. tech companies, is in trouble with the U.S. government again for possibly violating U.S. sanctions against Iran.

Congress claims the drug companies purposely misclassify drugs as generic instead of brand name to avoid paying higher rebates to Medicaid, and that it’s costing taxpayers millions of dollars.

Will it live up to the name?

US to follow China’s example and buy stocks when the market plunges?